Characterizing Biologics Using Dynamic Imaging Particle Analysis - Overcoming limitations of volumetric techniques and detecting transparent particles. - BioPharm International


Characterizing Biologics Using Dynamic Imaging Particle Analysis
Overcoming limitations of volumetric techniques and detecting transparent particles.

BioPharm International Supplements
Volume 24, Issue 8, pp. s4-s9

Because the filtering operations that automatically separate various particle types in imaging particle analysis are based on the image measurements, it seems to follow that less-than-sharp images with inaccurate measurements would not produce good-quality particle characterization. To demonstrate this idea with protein aggregates, the author analyzed a sample protein-based therapeutic with the FlowCAM using a deeper-than-normal flow cell to yield particle images of varying sharpness. Two image libraries were created for use with a statistical pattern-recognition algorithm. One contained eight aggregate images in sharp focus, and the other contained eight aggregate images in less sharp focus. Each library was then used to perform a statistical pattern match on the entire run of aggregate particles.

The results are shown in Figure 6. Sixty percent fewer aggregates were found using the less focused library images. In statistical filtering, this occurs because the library particles form a looser, more ambiguous cluster in the n-dimensional pattern-recognition space because of the higher variance in measurements (3). This cluster, in turn, yields lower statistical confidence in the identity of the library particles, and therefore a lower match rate.

Figure 6: Results of statistical pattern recognition with two libraries of various image quality. Results on left (152 particles/mL) used the sharp library particles, and results on the right (91 particles/mL) used the less sharp library particles.
Not only will the resulting match rate be lower for less sharp particle libraries, but the inaccuracy of the measurements can also lead to false positives. To summarize this discussion of image quality: Fuzzy Images = Fuzzy Measurements = Fuzzy Classifications.

For the characterization of protein aggregates and other particulates in biologics, volumetric techniques such as light obscuration, laser diffraction, and electrozone (Coulter) sensing have limited effectiveness because of the fact that each must assume that particles are spherical in shape. This assumption means that the techniques cannot distinguish between protein aggregates and other particulates, such as silicone droplets, found in biologics.

Imaging particle analysis can overcome the limitations of these volumetric techniques by measuring shape and gray-scale parameters of particles. It also has the benefit of detecting transparent particles, such as protein aggregates, where techniques such as light obscuration fail or mischaracterize the particles. However, as with any other method of particle analysis, it is important to understand the limitations and factors that affect particle measurements using this method. This article has shown that three factors must be kept in mind when evaluating the efficacy of an imaging particle analysis solution for characterizing biologics: resolution, thresholding, and image quality. Once these factors are understood, one can have higher confidence in one's interpretation of results based on this technique.

LEW BROWN is the director of marketing at Fluid Imaging Technologies, 65 Forest Falls Dr., Yarmouth, ME 04096,


1. S. Aldrich, US Pharmacopeia Workshop on Particle Size: Particle Detection and Measurement (Rockville, MD, 2010).

2. J.F. Carpenter et al., J. Pharm. Sci. 98 (4), 1201–1205 (2009)

3. L. Brown, "Particle Image Understanding–A Primer,", accessed July 12, 2011.

4. L.Brown, "Imaging Particle Analysis: Resolution and Sampling Considerations,", accessed July 12, 2011.

5. J.S. Pedersen, Bio-Process International European Conference and Exposition (Nice, France, 2011).

6. L. Brown, "Imaging Particle Analysis: The Importance of Image Quality,", accessed July 12, 2011.

blog comments powered by Disqus



AbbVie/Shire Deal Officially Off
October 20, 2014
Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9
October 20, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Lilly to Close Manufacturing Facility in Puerto Rico
October 17, 2014
BioReliance Introduces New Predictive Assays
October 17, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here